MLX-interacting protein (MLXIP)

MLX-interacting protein (MLXIP, also called MondoA) is a glucose-responsive transcription factor of the basic helix-loop-helix-leucine zipper (bHLH-ZIP) protein family[3][4]. It acts as a nutrient sensor by forming heterodimers with Max-like protein X (MLX) and detects intracellular glucose metabolites (notably glucose-6-phosphate). When glucose levels rise, MLXIP/MondoA translocates to the nucleus and activates transcription of genes such as TXNIP and key glycolytic enzymes, which create a negative feedback to regulate glucose uptake and metabolism[3]. MLXIP is central to energy homeostasis and links mitochondrial signals to nuclear gene expression. Its function extends to metabolic reprogramming during cancer development, where aberrant activity can promote tumor survival under metabolic stress. MondoA is expressed most abundantly in muscle and regulates the glycolytic pathway, distinguishing it from its close paralog ChREBP (MLXIPL), which predominates in the liver[2][3]. Both are evolutionarily conserved and critical for vertebrate glucose sensing and metabolic regulation. There are no known approved drugs that directly target MLXIP; however, its key regulatory role in glucose metabolism and oncogenic signaling has made it a candidate for future therapeutic exploration[3][4].

Other names

MondoABHLHE36KIAA0867MIRMONDOAbHLHe36Transcriptional activator MondoAClass E basic helix-loop-helix protein 36Mlx interactor

Not directly targeted by approved drugs; however, therapeutic strategies could involve modulating transcriptional activity, nutrient sensing, or metabolic pathway regulation in disease settings[3].